📋 Official FDA Update: GLP-1 Safety Review Results (Jan 2026)

Peptide Library (Read Only)
1

Important updates straight from FDA.gov:

Big News: Suicidal Ideation Warning Being Removed

FDA is requesting removal of SI/B warnings from GLP-1 medications including Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide).

The Data: FDA reviewed 91 trials with 107,910 patients and found NO increased risk for:

  • Suicidal ideation/behavior
  • Anxiety, depression, or psychosis

This is excellent news for the community!

Source: FDA January 2026 Update

Shortage Status Updates

  • Semaglutide - Shortage RESOLVED (Feb 2025)
  • Tirzepatide - Shortage RESOLVED (Oct 2024)

FDA confirmed manufacturers can now meet national demand.

Source: FDA Drug Safety Announcement

FDA Warning on Compounded Products

FDA has identified fraudulent compounded products with:

  • Fake pharmacy names on labels
  • Doses beyond approved labeling causing adverse events
  • Serious symptoms requiring medical attention

Always verify your pharmacy is state-licensed and can provide certificates of analysis.

Source: FDA Safety Notice

Questions about these FDA updates? Drop them below! :backhand_index_pointing_down:

2

This is great news about the SI/B warning removal! I remember when that warning first came out - it scared a lot of people unnecessarily.

Good to see the FDA actually did a thorough review with real data. 107,000+ patients is a solid sample size.

The compounding warning is important though. I’ve seen some sketchy “pharmacies” advertising on social media lately. Always do your research before ordering from anywhere.

1 Like
3

omg same!! this is exactly what happened to me…